국가: 미국
언어: 영어
출처: NLM (National Library of Medicine)
isoxsuprine hydrochloride (UNII: V74TEQ36CO) (Isoxsuprine - UNII:R15UI3245N)
Bi-Coastal Pharmaceutical Corporation
isoxsuprine hydrochloride
isoxsuprine hydrochloride 10 mg
ORAL
PRESCRIPTION DRUG
Based on a review of this drug by the National Academy of Sciences-National Research and/or other information, the FDA has classified the indications as follows: - For the relief of symptoms associated with cerebrovascular insufficiency. - In peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's disease) and Raynaud's disease. Final classification of the less-than-effective indications requires further investigation. There are no known contraindications to oral use when administered in recommended doses. Isoxsuprine Hydrochloride, USP should not be given immediately postpartum or in the presence of arterial bleeding.
Isoxsuprine HCl tablets, USP 10 mg Bottles of 100 NDC 42582-100-10 Isoxsuprine HCl tablets, USP 20 mg Bottles of 1000 NDC 42582-200-20 Isoxsuprine HCl tablets, USP 20 mg Bottles of 100 NDC 42582-200-10 Isoxsuprine HCl 10mg and 20mg tablets: These tablets contain the following inactive ingredients: corn starch, lactose monohydrate, magnesium stearate (vegetable), microcrystalline cellulose. Distributed By: Bi-Coastal Pharmaceutical Corp. ® Red Bank, NJ 07701 Iss. 1/12
unapproved drug other
ISOXSUPRINE HYDROCHLORIDE- ISOXSUPRINE HYDROCHLORIDE TABLET BI-COASTAL PHARMACEUTICAL CORPORATION _Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been_ _approved by FDA. For further information about unapproved drugs, click here._ ---------- ISOXSUPRINE HYDROCHLORIDE TABLETS, USP RX ONLY DESCRIPTION Each tablet taken orally contains Isoxsuprine Hydrochloride, USP with the following chemical structure: C H NO • HCl p-Hydroxy-α[1-[(methyl-2-phenoxy-ethyl)amino]ethyl]benzyl alcohol hydrochloride. QUANTITATIVE INGREDIENT INFORMATION Each tablet taken orally contains 10 or 20 mg Isoxsuprine HCl PHARMACOLOGICAL CLASS Peripheral Vasodilator INDICATIONS Based on a review of this drug by the National Academy of Sciences-National Research and/or other information, the FDA has classified the indications as follows: POSSIBLY EFFECTIVE 1. For the relief of symptoms associated with cerebrovascular insufficiency. 2. In peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's disease) and Raynaud's disease. Final classification of the less-than-effective indications requires further investigation. CONTRAINDICATIONS There are no known contraindications to oral use when administered in recommended doses. Isoxsuprine Hydrochloride, USP should not be given immediately postpartum or in the presence of 18 23 3 arterial bleeding. PRECAUTIONS PEDIATRIC USE Safety and effectiveness in pediatric patients have not been established. ADVERSE REACTIONS On rare occasion oral administration of the drug has been associated in time with the occurrence of hypotension, tachycardia, chest pain, nausea, vomiting, dizziness, abdominal distress, and severe rash. If rash appears, the drug should be discontinued. Although available evidence suggests a temporal association of these reactions with Isoxsuprine Hydrochloride, a causal relationship can be neither confirmed nor refuted. Beta Adrenergic receptor stimulants such as Isoxsuprine Hydrocholoride have been 전체 문서 읽기